1
|
Liu X, Tian W, Dai A, Li H, Zhu M, Zeng M, Feng R, Zhang Z, Jiang X, Wen Y, Wu T, Xiao Z. A comparative analysis of toxicity and treatment outcomes of adaptive radiotherapy and intensity-modulated radiotherapy in cervical cancer. Sci Rep 2025; 15:1609. [PMID: 39794450 PMCID: PMC11724102 DOI: 10.1038/s41598-024-85074-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Accepted: 12/31/2024] [Indexed: 01/13/2025] Open
Abstract
Adaptive radiotherapy (ART) provides greater benefits than intensity-modulated radiotherapy (IMRT) regarding dosimetric outcomes in patients with cervical cancer. To investigate the clinical benefits of ART, we have collected data from 115 cervical cancer patients who underwent radical radiotherapy at our institution. Fifty-nine patients received a single course of IMRT. Fifty-six patients underwent offline ART, defined as the reduction of the gross tumor volume (GTV) by at least 30% after 30 Gy of radiotherapy, followed by a modified treatment plan for the second-stage. After treatment, 53 patients of ART group achieved a partial response (PR) or completement response (CR), resulting in an objective response rate (ORR) of 94.6% for the ART group, compared to 93.2% for the IMRT group. Patients in both groups exhibited no significant differences in acute toxicities. However, the incidence of chronic constipation was significantly higher in the IMRT group compared to the ART group (p = 0.021). With a median follow-up time of 27 months, the ART group experienced a higher mortality (10/56) than the IMRT group (6/59). However, the difference between the two groups was not statistically significant. In summary, ART may be advantageous in reducing the incidence of chronic constipation among patients with locally advanced cervical cancer, and both clinical prognosis and near-term survival are satisfactory.
Collapse
Affiliation(s)
- Xiaohan Liu
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Wei Tian
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Anli Dai
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Hui Li
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Mei Zhu
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Mengsi Zeng
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Ronghua Feng
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Zhenyu Zhang
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Xiaosong Jiang
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Yu Wen
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China
- The First People's Hospital of Changde City, Changde, China
| | - Tao Wu
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China.
- The First People's Hospital of Changde City, Changde, China.
| | - Zemin Xiao
- Changde Hospital, Xiangya School of Medicine, Central South University, Renmin Road 818, Changde, 415000, China.
- The First People's Hospital of Changde City, Changde, China.
| |
Collapse
|
2
|
Peng H, Zhang J, Xu N, Zhou Y, Tan H, Ren T. Fan beam CT-guided online adaptive external radiotherapy of uterine cervical cancer: a dosimetric evaluation. BMC Cancer 2023; 23:588. [PMID: 37365516 DOI: 10.1186/s12885-023-11089-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 06/20/2023] [Indexed: 06/28/2023] Open
Abstract
PURPOSE To discuss the dosimetric advantages and reliability of the accurate delivery of online adaptive radiotherapy(online ART) for uterine cervical cancer(UCC). METHODS AND MATERIALS Six UCC patients were enrolled in this study. 95% of the planning target volume (PTV) reached 100% of the prescription dose (50.4 Gy/28fractions/6weeks) was required. The patients were scanned with uRT-Linac 506c KV-FBCT then the target volume (TV) and organs at risk (OARs) were delineated by doctors. The dosimeters designed and obtained a routine plan (Plan0). KV-FBCT was used for image guidance before subsequent fractional treatment. The online ART was processed after registration, which acquired a virtual nonadaptive radiotherapy plan (VPlan) and an adaptive plan (APlan). VPlan was the direct calculation of Plan0 on the fractional image, while APlan required adaptive optimization and calculation. In vivo dose monitoring and three-dimensional dose reconstruction were required during the implementation of APlan. RESULTS The inter-fractional volumes of the bladder and rectum changed greatly among the treatments. These changes influenced the primary gross tumor volume (GTVp) and the position deviation of GTVp and PTV and positively affected the prescription dose coverage of TV. GTVp decreased gradually along with dose accumulation. The Dmax, D98, D95, D50, and D2 of APlan were superior to those of VPlan in target dose distribution. APlan had good conformal index, homogeneity index and target coverage. The rectum V40 and Dmax, bladder V40, the small bowel V40 and Dmax of APlan were better than that of VPlan. The APlan's fractional mean γ passing rate was significantly higher than the international standard and the mean γ passing rate of all cases after the three-dimensional reconstruction was higher than 97.0%. CONCLUSION Online ART in external radiotherapy of UCC significantly improved the dose distribution and can become an ideal technology to achieve individualized precise radiotherapy.
Collapse
Affiliation(s)
- Haibo Peng
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
- Key Clinical Specialty of Sichuan Province (Oncology Department), The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
- Clinical Medical School, Chengdu Medical College, Chengdu, 610500, China
| | - Jie Zhang
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
- Key Clinical Specialty of Sichuan Province (Oncology Department), The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
- Clinical Medical School, Chengdu Medical College, Chengdu, 610500, China
| | - Ningyue Xu
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
| | - Yangang Zhou
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
| | - Huigang Tan
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China
| | - Tao Ren
- Oncology Department, The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
- Key Clinical Specialty of Sichuan Province (Oncology Department), The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, China.
- Clinical Medical School, Chengdu Medical College, Chengdu, 610500, China.
| |
Collapse
|
3
|
MRI-guided Radiotherapy (MRgRT) for treatment of Oligometastases: Review of clinical applications and challenges. Int J Radiat Oncol Biol Phys 2022; 114:950-967. [PMID: 35901978 DOI: 10.1016/j.ijrobp.2022.07.027] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 07/18/2022] [Accepted: 07/19/2022] [Indexed: 11/23/2022]
Abstract
PURPOSE Early clinical results on the application of magnetic resonance imaging (MRI) coupled with a linear accelerator to deliver MR-guided radiation therapy (MRgRT) have demonstrated feasibility for safe delivery of stereotactic body radiotherapy (SBRT) in treatment of oligometastatic disease. Here we set out to review the clinical evidence and challenges associated with MRgRT in this setting. METHODS AND MATERIALS We performed a systematic review of the literature pertaining to clinical experiences and trials on the use of MRgRT primarily for the treatment of oligometastatic cancers. We reviewed the opportunities and challenges associated with the use of MRgRT. RESULTS Benefits of MRgRT pertaining to superior soft-tissue contrast, real-time imaging and gating, and online adaptive radiotherapy facilitate safe and effective dose escalation to oligometastatic tumors while simultaneously sparing surrounding healthy tissues. Challenges concerning further need for clinical evidence and technical considerations related to planning, delivery, quality assurance (QA) of hypofractionated doses, and safety in the MRI environment must be considered. CONCLUSIONS The promising early indications of safety and effectiveness of MRgRT for SBRT-based treatment of oligometastatic disease in multiple treatment locations should lead to further clinical evidence to demonstrate the benefit of this technology.
Collapse
|
4
|
Hu YH, Harper RH, Deiter NC, Evans JD, Mahajan A, Kruse JJ, Mundy DW. Analysis of the Rate of Re-planning in Spot-Scanning Proton Therapy. Int J Part Ther 2022; 9:49-58. [PMID: 36060413 PMCID: PMC9415746 DOI: 10.14338/ijpt-21-00043.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 05/19/2022] [Indexed: 12/04/2022] Open
Abstract
Purpose Finite proton range affords improved dose conformality of radiation therapy when patient regions-of-interest geometries are well characterized. Substantial changes in patient anatomy necessitate re-planning (RP) to maintain effective, safe treatment. Regularly planned verification scanning (VS) is performed to ensure consistent treatment quality. Substantial resources, however, are required to conduct an effective proton plan verification program, which includes but is not limited to, additional computed tomography (CT) scanner time and dedicated personnel: radiation therapists, medical physicists, physicians, and medical dosimetrists. Materials and Methods Verification scans (VSs) and re-plans (RPs) of 711 patients treated with proton therapy between June 2015 and June 2018 were studied. All treatment RP was performed with the intent to maintain original plan integrity and coverage. The treatments were classified by anatomic site: brain, craniospinal, bone, spine, head and neck (H&N), lung or chest, breast, prostate, rectum, anus, pelvis, esophagus, liver, abdomen, and extremity. Within each group, the dates of initial simulation scan, number of VSs, number of fractions completed at the time of VS, and the frequency of RP were collected. Data were analyzed in terms of rate of RP and individual likelihood of RP. Results A total of 2196 VSs and 201 RPs were performed across all treatment sites. H&N and lung or chest disease sites represented the largest proportion of plan modifications in terms of rate of re-plan (RoR: 54% and 58%, respectively) and individual likelihood of RP on a per patient basis (likelihood of RP [RP%]: 46% and 39%, respectively). These sites required RP beyond 4 weeks of treatment, suggesting continued benefit for frequent, periodic VS. Disease sites in the lower pelvis demonstrated a low yield for RP per VS (0.01-0.02), suggesting that decreasing VS frequency, particularly late in treatment, may be reasonable. Conclusions A large degree of variation in RoR and individual RP% was observed between anatomic treatment sites. The present retrospective analysis provides data to help develop anatomic site–based VS protocols.
Collapse
Affiliation(s)
- Yue-Houng Hu
- 1 Department of Radiation Oncology, Division of Medical Physics, Mayo Clinic, Rochester, MN, USA
| | - Riley H. Harper
- 2 College of Science and Engineering, University of Minnesota, Minneapolis, MN, USA
| | - Noelle C. Deiter
- 3 Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
| | - Jaden D. Evans
- 3 Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
- 4 Department of Radiation Oncology and Precision Genomics, Intermountain Cancer Center, Ogden, UT, USA
| | - Anita Mahajan
- 3 Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
| | - Jon J. Kruse
- 1 Department of Radiation Oncology, Division of Medical Physics, Mayo Clinic, Rochester, MN, USA
| | - Daniel W. Mundy
- 1 Department of Radiation Oncology, Division of Medical Physics, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
5
|
Mao W, Riess J, Kim J, Vance S, Chetty IJ, Movsas B, Kretzler A. Evaluation of auto-contouring and dose distributions for online adaptive radiation therapy of patients with locally advanced lung cancers. Pract Radiat Oncol 2022; 12:e329-e338. [DOI: 10.1016/j.prro.2021.12.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 12/14/2021] [Accepted: 12/26/2021] [Indexed: 11/28/2022]
|
6
|
Shelley CE, Barraclough LH, Nelder CL, Otter SJ, Stewart AJ. Adaptive Radiotherapy in the Management of Cervical Cancer: Review of Strategies and Clinical Implementation. Clin Oncol (R Coll Radiol) 2021; 33:579-590. [PMID: 34247890 DOI: 10.1016/j.clon.2021.06.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Revised: 05/19/2021] [Accepted: 06/11/2021] [Indexed: 02/08/2023]
Abstract
The complex and varied motion of the cervix-uterus target during external beam radiotherapy (EBRT) underscores the clinical benefits afforded by adaptive radiotherapy (ART) techniques. These gains have already been realised in the implementation of image-guided adaptive brachytherapy, where adapting to anatomy at each fraction has seen improvements in clinical outcomes and a reduction in treatment toxicity. With regards to EBRT, multiple adaptive strategies have been implemented, including a personalised internal target volume, offline replanning and a plan of the day approach. With technological advances, there is now the ability for real-time online ART using both magnetic resonance imaging and computed tomography-guided imaging. However, multiple challenges remain in the widespread dissemination of ART. This review investigates the ART strategies and their clinical implementation in EBRT delivery for cervical cancer.
Collapse
Affiliation(s)
- C E Shelley
- Department of Clinical Oncology, St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK.
| | - L H Barraclough
- Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK
| | - C L Nelder
- Department of Radiotherapy, The Christie NHS Foundation Trust, Manchester, UK
| | - S J Otter
- Department of Clinical Oncology, St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK
| | - A J Stewart
- Department of Clinical Oncology, St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK; University of Surrey, Guildford, UK
| |
Collapse
|
7
|
Abstract
As deformable image registration makes its way into the clinical routine, the summation of doses from fractionated treatment regimens to evaluate cumulative doses to targets and healthy tissues is also becoming a frequently utilized tool in the context of image-guided adaptive radiotherapy. Accounting for daily geometric changes using deformable image registration and dose accumulation potentially enables a better understanding of dose-volume-effect relationships, with the goal of translation of this knowledge to personalization of treatment, to further enhance treatment outcomes. Treatment adaptation involving image deformation requires patient-specific quality assurance of the image registration and dose accumulation processes, to ensure that uncertainties in the 3D dose distributions are identified and appreciated from a clinical relevance perspective. While much research has been devoted to identifying and managing the uncertainties associated with deformable image registration and dose accumulation approaches, there are still many unanswered questions. Here, we provide a review of current deformable image registration and dose accumulation techniques, and related clinical application. We also discuss salient issues that need to be deliberated when applying deformable algorithms for dose mapping and accumulation in the context of adaptive radiotherapy and response assessment.
Collapse
|